Solid forms comprising (5r,6s)-10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1h-spiro[benzo[b][1,5,4]oxathiazecina-3,1'-cyclopropane] 2,2-dioxide, and compositions comprising them and methods of use thereof

Abstract

Solid forms of (5R,6S)-10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1H-spiro[benzo[b][1,5,4]oxatiazecina-3,1'-cyclopropane] 2,2-dioxide are described herein in amorphous and crystalline forms, along with processes for preparing and pharmaceutical compositions thereof. Methods for their use in treating, preventing, or improving a disease or disorder in which the RAS pathway is upregulated, such as cancer, RASopathies, and laminopathies, are also provided. Formula (I).